X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TORRENT PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS TORRENT PHARMA IPCA LABS/
TORRENT PHARMA
 
P/E (TTM) x 35.6 36.7 97.1% View Chart
P/BV x 3.4 5.7 59.2% View Chart
Dividend Yield % 0.2 1.0 16.0%  

Financials

 IPCA LABS   TORRENT PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
TORRENT PHARMA
Mar-17
IPCA LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6431,768 36.4%   
Low Rs5031,186 42.4%   
Sales per share (Unadj.) Rs254.4346.1 73.5%  
Earnings per share (Unadj.) Rs16.155.2 29.1%  
Cash flow per share (Unadj.) Rs29.873.3 40.6%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.20.9 18.4%  
Book value per share (Unadj.) Rs194.6257.1 75.7%  
Shares outstanding (eoy) m126.20169.22 74.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.3 52.8%   
Avg P/E ratio x35.726.8 133.2%  
P/CF ratio (eoy) x19.220.1 95.5%  
Price / Book Value ratio x2.95.7 51.3%  
Dividend payout %6.225.4 24.5%   
Avg Mkt Cap Rs m72,300249,887 28.9%   
No. of employees `00013.311.8 112.9%   
Total wages/salary Rs m6,9609,934 70.1%   
Avg. sales/employee Rs Th2,413.54,971.5 48.5%   
Avg. wages/employee Rs Th523.2843.2 62.0%   
Avg. net profit/employee Rs Th152.4792.4 19.2%   
INCOME DATA
Net Sales Rs m32,10658,569 54.8%  
Other income Rs m2262,233 10.1%   
Total revenues Rs m32,33260,802 53.2%   
Gross profit Rs m4,44813,773 32.3%  
Depreciation Rs m1,7303,069 56.4%   
Interest Rs m2412,056 11.7%   
Profit before tax Rs m2,70310,881 24.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6751,545 43.7%   
Profit after tax Rs m2,0289,336 21.7%  
Gross profit margin %13.923.5 58.9%  
Effective tax rate %25.014.2 175.9%   
Net profit margin %6.315.9 39.6%  
BALANCE SHEET DATA
Current assets Rs m17,34053,841 32.2%   
Current liabilities Rs m9,55931,612 30.2%   
Net working cap to sales %24.238.0 63.9%  
Current ratio x1.81.7 106.5%  
Inventory Days Days10097 103.2%  
Debtors Days Days5784 67.9%  
Net fixed assets Rs m20,77942,079 49.4%   
Share capital Rs m252846 29.8%   
"Free" reserves Rs m24,49942,655 57.4%   
Net worth Rs m24,55343,501 56.4%   
Long term debt Rs m3,51722,408 15.7%   
Total assets Rs m39,595101,250 39.1%  
Interest coverage x12.26.3 194.3%   
Debt to equity ratio x0.10.5 27.8%  
Sales to assets ratio x0.80.6 140.2%   
Return on assets %5.711.3 50.9%  
Return on equity %8.321.5 38.5%  
Return on capital %10.519.6 53.4%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61720,066 77.8%   
Fx outflow Rs m5,8285,304 109.9%   
Net fx Rs m9,79014,762 66.3%   
CASH FLOW
From Operations Rs m2,76410,127 27.3%  
From Investments Rs m-1,432-7,869 18.2%  
From Financial Activity Rs m-1,591-1,918 83.0%  
Net Cashflow Rs m-259212 -122.4%  

Share Holding

Indian Promoters % 45.9 71.5 64.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.0 162.4%  
FIIs % 25.3 12.6 200.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.8 197.7%  
Shareholders   36,892 26,511 139.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 22, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - WYETH LTD COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS